Q1 Earnings Forecast for Immunome Issued By Lifesci Capital

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at Lifesci Capital issued their Q1 2025 EPS estimates for Immunome in a research report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($0.61) per share for the quarter. Lifesci Capital has a "Outperform" rating and a $20.00 price target on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

Separately, Wedbush reaffirmed an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, March 10th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Immunome currently has an average rating of "Buy" and an average target price of $27.17.

Immunome Trading Down 1.8 %

IMNM stock traded down $0.16 on Thursday, hitting $8.77. 453,030 shares of the company's stock traded hands, compared to its average volume of 896,133. Immunome has a 1-year low of $8.39 and a 1-year high of $26.70. The stock has a fifty day moving average of $9.98 and a 200-day moving average of $11.78. The stock has a market cap of $699.64 million, a price-to-earnings ratio of -1.08 and a beta of 1.93.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new position in shares of Immunome during the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS bought a new position in shares of Immunome during the 4th quarter valued at $75,000. AlphaQuest LLC raised its holdings in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome during the 4th quarter valued at $95,000. Institutional investors own 44.58% of the company's stock.

Insiders Place Their Bets

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the business's stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares of the company's stock, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 8.60% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.